A Phase 2 interventional study of Hypericin in Psoriasis, Plaque Psoriasis and Psoriasis Vulgaris, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Soligenix · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.
Among the 766 studies in Psoriasis with a site in United States, this one is the 587th largest by enrollment of the 675 interventional ones that give a count, is one of 37 that started in 2022, is one of 200 in phase 2, and was the 657th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
766 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 37 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 675 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 378 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
526 of 766 have an industry lead sponsor. The 10 most frequent:
Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Soligenix has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
24 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 766 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a gradual escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
Drug: Hypericin
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
Drug: Hypericin
SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 40 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
Drug: Hypericin
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Also known as: SGX302
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions
Time frame: 18 weeks
SkinDex-29 Score
The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome.
Time frame: Baseline, End of Treatment (Week 18)
Dermatology Life Quality Index Score
The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome.
Time frame: Baseline, End of Treatment (Week 18)
| Milestone | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 4 | 3 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions
| Participants | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) |
|---|---|---|---|
| Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale | 0 | 1 | 1 |
The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome.
| Scores on a Scale | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) |
|---|---|---|---|
| Baseline | 76 ± 30 | 59 ± 15 | 92 ± 26 |
| End of Treatment | 74 ± 20 | 55 ± 24 | 78 ± 23 |
The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome.
| Scores on a Scale | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) |
|---|---|---|---|
| Baseline | 6 ± 5 | 3 ± 1 | 16 ± 10 |
| End of Treatment | 5 ± 3 | 4 ± 4 | 12 ± 6 |
Collected over Adverse events were collected from enrollment until end of follow-up, up to 22 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 3 - SGX302 Gel (0.25 % Hypericin) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Event | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) |
|---|---|---|---|
| Left axillary lymphadenopathyBlood and lymphatic system disorders | 1/5 | 0/5 | 0/5 |
| Eye irritationEye disorders | 0/5 | 1/5 | 0/5 |
| Pain localizedGeneral disorders | 0/5 | 1/5 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 1/5 | 1/5 | 0/5 |
| NasopharyngitisInfections and infestations | 1/5 | 0/5 | 0/5 |
| InfluenzaInfections and infestations | 0/5 | 1/5 | 0/5 |
| Left lower leg abscessInfections and infestations | 0/5 | 0/5 | 1/5 |
| SunburnInjury, poisoning and procedural complications | 1/5 | 0/5 | 0/5 |
| Muscle strainInjury, poisoning and procedural complications | 1/5 | 0/5 | 0/5 |
| Contusion of toeInjury, poisoning and procedural complications | 1/5 | 0/5 | 0/5 |
| Age, Continuous(years) | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) | Total |
|---|---|---|---|---|
| Mean | 54 ± 5.0 | 45 ± 10.8 | 56 ± 9.5 | 52 ± 9.6 |
| Sex: Female, Male(Participants) | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 2 | 10 |
| Male | 1 | 1 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 3 | 5 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - SGX302 Ointment (0.25 % Hypericin) | Cohort 2 - SGX302 Ointment (0.25 % Hypericin) | Cohort 3 - SGX302 Gel (0.25 % Hypericin) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 3 | 8 |
| Not Hispanic or Latino | 2 | 3 | 2 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Oct 2025, 34 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 34 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hypericin
Soligenix